Double Monoclonal Immunoassay for Quantifying Human Visinin-Like Protein-1 in CSF

Crimmins, Daniel L.; Herries, Elizabeth M.; Ohlendorf, Matthew F.; Brada, Nancy; Garbett, Nichola C.; Zipfel, Gregory J.; Schindler, Suzanne E.; Ladenson, Jack H.

doi:10.1373/clinchem.2016.263236

Cited by 5 publications

(6 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Concentrations of Aβ40, Aβ42, total tau, and p‐tau were measured by chemiluminescent enzyme immunoassay using a fully automated platform (LUMIPULSE G1200, Fujirebio, Malvern, PA) according to manufacturer's specifications. Ng, SNAP‐25, and VILIP‐1 were measured with microparticle‐based immunoassays using Single Molecule Counting technology employing antibodies developed in the laboratory of Dr. Jack Ladenson at Washington University in St. Louis, as described previously 8,10,23 . Concentrations of sTREM2 were measured via an in‐house enzyme‐linked immunosorbent assay (ELISA) as described previously 12 .…”

Section: Methodsmentioning

confidence: 99%

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome

Henson

Doran

Christian

et al. 2020

Alzheimer's & Dementia: Diagnosis, Assessment &

View full text Add to dashboard Cite

Introduction Virtually all individuals with Down syndrome (DS) will develop Alzheimer's disease (AD) pathology by age 40. Cerebrospinal fluid (CSF) biomarkers have characterized AD pathology in cohorts of late‐onset AD (LOAD) and autosomal‐dominant AD (ADAD). Few studies have evaluated such biomarkers in adults with DS. Methods CSF concentrations of amyloid beta (Aβ)40, Aβ42, tau, phospho‐tau181 (p‐tau), neurofilament light chain (NfL), soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase‐3‐like protein 1 (YKL‐40), alpha synuclein (αSyn), neurogranin (Ng), synaptosomal‐associated protein 25 (SNAP‐25), and visinin‐like protein 1 (VILIP‐1) were assessed in CSF from 44 adults with DS from the Alzheimer's Biomarker Consortium–Down Syndrome study. Biomarker levels were evaluated by cognitive status, age, and apolipoprotein E gene ( APOE ) ε4 carrier status. Results Biomarker abnormalities indicative of amyloid deposition, tauopathy, neurodegeneration, synaptic dysfunction, and neuroinflammation were associated with increased cognitive impairment. Age and APOE ε4 status influenced some biomarkers. Discussion The profile of many established and emerging CSF biomarkers of AD in a cohort of adults with DS was similar to that reported in LOAD and ADAD, while some differences were observed.

show abstract

Section: Methodsmentioning

confidence: 99%

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome

Henson

Doran

Christian

et al. 2020

Alzheimer's & Dementia: Diagnosis, Assessment &

View full text Add to dashboard Cite

show abstract

“…Fujirebio kit‐provided controls and in‐house fluid biomarker core CSF controls were used for quality control purposes (see supplemental materials for assay measurement range and quality control performance in Tables S6, S7, S8, and S9). VILIP‐1, SNAP‐25, and Ng were measured by quantitative fluorescent two‐site immunoassays with Single Molecule Counting (SMC) technology using antibodies and protocols developed in the laboratory of Dr. Jack Ladenson at Washington University in St. Louis, as was previously described 14,19–21 . Samples and in‐house CSF controls (Tables S10 and S11) were analyzed over 7 days, 27 samples per day.…”

Section: Methodsmentioning

confidence: 99%

“…VILIP-1, SNAP-25, and Ng were measured by quantitative fluorescent two-site immunoassays with Single Molecule Counting (SMC) technology using antibodies and protocols developed in the laboratory of Dr. Jack Ladenson at Washington University in St. Louis, as was previously described. 14,[19][20][21] Samples and in-house CSF controls (Tables S10 and S11) were analyzed over 7 days, 27 samples per day.…”

Section: Participantsmentioning

confidence: 99%

Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study

Dage,

Eloyan,

Thangarajah

et al. 2023

Alzheimer's & Dementia

View full text Add to dashboard Cite

IntroductionOne goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early‐onset Alzheimer's disease (EOAD).MethodsCerebrospinal fluid (CSF) concentrations of Aβ1‐40, Aβ1‐42, total tau (tTau), pTau181, VILIP‐1, SNAP‐25, neurogranin (Ng), neurofilament light chain (NfL), and YKL‐40 were measured by immunoassay in 165 LEADS participants. The associations of biomarker concentrations with diagnostic group and standard cognitive tests were evaluated.ResultsBiomarkers were correlated with one another. Levels of CSF Aβ42/40, pTau181, tTau, SNAP‐25, and Ng in EOAD differed significantly from cognitively normal and early‐onset non‐AD dementia; NfL, YKL‐40, and VILIP‐1 did not. Across groups, all biomarkers except SNAP‐25 were correlated with cognition. Within the EOAD group, Aβ42/40, NfL, Ng, and SNAP‐25 were correlated with at least one cognitive measure.DiscussionThis study provides a comprehensive analysis of CSF biomarkers in sporadic EOAD that can inform EOAD clinical trial design.

show abstract

“…Concentrations of CSF Aβ40, Aβ42, total tau, and total p‐tau (181) were measured by chemiluminescent enzyme immunoassay using an automated platform (LUMIPULSE G1200, Fujirebio) according to the manufacturer's specifications. CSF Neurogranin, SNAP‐25, and VILIP‐1 were measured with microparticle‐based immunoassays using Single Molecule Counting technology 17,35,36 . CSF YKL‐40 (Quidel) was measured via commercial enzyme‐linked immunosorbent assays (ELISAs) according to manufacturer's recommendations.…”

Section: Methodsmentioning

confidence: 99%

“…13 CSF (10 Counting technology. 17,35,36 CSF YKL-40 (Quidel) was measured via commercial enzyme-linked immunosorbent assays (ELISAs) according to manufacturer's recommendations. CSF p-tau extracts were analyzed by nanoLC-MS/HRMS using Parallel Reaction Monitoring using higher energy collisional dissociation (HCD) fragmentation.…”

Section: Csf Acquisition and Processingmentioning

confidence: 99%

Biomarker clustering in autosomal dominant Alzheimer's disease

Luckett

Chen

Gordon

et al. 2022

Alzheimer's & Dementia

View full text Add to dashboard Cite

INTRODUCTION:As the number of biomarkers used to study Alzheimer's disease (AD) continues to increase, it is important to understand the utility of any given biomarker, as well as what additional information a biomarker provides when compared to others. METHODS:We used hierarchical clustering to group 19 cross-sectional biomarkers in autosomal dominant AD. Feature selection identified biomarkers that were the strongest predictors of mutation status and estimated years from symptom onset (EYO). Biomarkers identified included clinical assessments, neuroimaging, cerebrospinal fluid amyloid, and tau, and emerging biomarkers of neuronal integrity and inflammation.RESULTS: Three primary clusters were identified: neurodegeneration, amyloid/tau, and emerging biomarkers. Feature selection identified amyloid and tau measures as the primary predictors of mutation status and EYO. Emerging biomarkers of neuronal integrity and inflammation were relatively weak predictors.DISCUSSION: These results provide novel insight into our understanding of the relationships among biomarkers and the staging of biomarkers based on disease progression.

show abstract

Double Monoclonal Immunoassay for Quantifying Human Visinin-Like Protein-1 in CSF

Cited by 5 publications

References 5 publications

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome

Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome

Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study

Biomarker clustering in autosomal dominant Alzheimer's disease

Contact Info

Product

Resources

About